We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FTC Says Biosimilar Substitution Should Shadow Generics Model
FTC Says Biosimilar Substitution Should Shadow Generics Model
The FTC last week said regulations and legislation governing the naming and dispensation of biosimilars should match those already in place for generic drugs to avoid chilling competition among drugmakers.